Who gains from saving nature
Ledger 1 : 33 — For each dollar financing nature-based solutions in 2023, about $33 financed activities harmful to nature. (UNEP)
Cases / Pesticides and agrochemicals · United States · 1958–2026

Paraquat litigation (Syngenta/Chevron) and the Paraquat Papers

Nature's voice · report
No measurement of the harm done to me here is on record.
Did nature suffer? Not measured.
What the record lacks: 5 none on record · 7 insufficient · 1 self-reported only · 1 not measured · 5 disputed See the gaps

Plaintiffs in the United States allege that the weed killer paraquat causes Parkinson's disease. Internal company documents released through litigation and published in 2022 and 2023 recorded decades of company findings on paraquat and the brain and efforts to influence science and regulators. By July 2026 more than 8,000 federal cases were pending and none had gone before a jury; Syngenta had settled without admitting liability and announced it would end Gramoxone sales.

8,000+Cases pending in the US federal paraquat litigation, July 2026
Up from more than 5,800 in April 2025; none had gone before a jury (The New Lede).

Status As of July 2026: more than 8,000 federal cases pending, none tried before a jury; Syngenta had announced the end of Gramoxone sales by 31 December 2026; the EPA review was ongoing.

What?
Litigation over the alleged link between paraquat exposure and Parkinson's disease, and the company records released through it. The New Lede (with The Guardian)
Where?
Federal courts in Illinois (MDL 3004); regulators and courts in the EU, Switzerland, Brazil and the UK; Syngenta is headquartered in Switzerland. The New Lede
When?
Internal records from 1958; settlement 2021; MDL settlement letter April 2025; Gramoxone exit announced 3 March 2026. The New Lede (with The Guardian)
Who?
Gained
Lost
  • Syngenta — Paid $187.5 million in 2021 and an undisclosed amount in 2025, without admitting liability
  • Plaintiffs in the settlement — Said little would remain after liens and fees from payments that some lawyers estimated at $100,000 or less. The New Lede
Harmed
  • Plaintiffs alleging Parkinson's disease from paraquat — More than 8,000 federal cases by July 2026; some lawyers estimated an average payment of $100,000 or less; plaintiffs said little would remain after liens and fees The New Lede
  • People in Paraná, Brazil — Diquat poisonings rose from 1–3 a year to 9 in 2023 as diquat took part of the market paraquat left
Why?
Plaintiffs allege paraquat causes Parkinson's disease; Syngenta says regulators judge it safe and no properly designed study establishes a link. The New Lede (with The Guardian)
How?
Through responses prepared by a "PQ SWAT team", edited scientists' statements, objections routed through CropLife America and a former EPA official as company expert. The New Lede / The Guardian
6 of 6 questions answered from the record

What happened

The record, in order.

Paraquat is a contact weed killer that Imperial Chemical Industries (ICI) developed in 1961 and sold as Gramoxone. ICI's agricultural arm later became Syngenta. Chevron was the US distributor from 1966 to 1986. Syngenta's headquarters are in Switzerland, which banned paraquat in 1989. Syngenta says US and Australian regulators judge paraquat safe, that no properly designed study has established a link to Parkinson's disease, and that more than 1,200 studies do not show causation.

Internal records released through litigation, published by The New Lede and The Guardian in 2022 and 2023 (the further SWAT-team files in June 2023) as the "Paraquat Papers", show that in 1958 ICI saw a related compound affect the nervous system, in 1966 observed tremors in rats and mice, and in 1968 found at autopsy that paraquat accumulated in the brain. An autopsy of an agricultural worker in 1976 showed cell degeneration in the substantia nigra, the brain region where cell loss occurs in Parkinson's disease. A 1985 Chevron note compared the legal risk to asbestos; Chevron stopped selling paraquat in 1986, citing increased competition. A 2003 document called the product a blockbuster and projected annual sales above $400 million. A 2003 company mouse study found no neuron loss and was disclosed; a researcher who repeated it with independent scientists' method found significant neuron loss, and that result was not published and reached the EPA only around 2019, after a lawyer threatened to send the data himself. In 2005 Syngenta, through the industry association CropLife America and without being named, argued against a critical scientist joining an EPA panel; the EPA did not select her in 2005 or in 2010 to 2011. By 2011 at the latest a "PQ SWAT team" worked to answer new studies, aiming at an international scientific consensus against the hypothesis that paraquat is a risk factor for Parkinson's. A defence lawyer had scientists' statements edited in 2008 to 2009, and Jack Housenger, a retired director of the EPA's pesticide office, became a company expert at $300 an hour. The New Lede wrote that the documents do not show Syngenta believed in a Parkinson's link; they show efforts to protect sales, answer outside research and influence the regulator.

In 2021 Syngenta settled paraquat claims for $187.5 million without admitting liability. In the consolidated federal cases in Illinois (MDL 3004) a settlement letter with an undisclosed amount was signed in April 2025, when more than 5,800 federal cases were pending. By July 2026 there were more than 8,000 and none had gone before a jury. The judge sent those who refused the settlement to a special master for meetings and depositions; 183 of one law firm's 217 clients left the settlement. Some lawyers estimated the average payment at $100,000 or less, and plaintiffs said little would remain after liens and fees. Syngenta says the settlement is not an admission of causation and that the cases lack merit.

The EPA's 2021 interim decision found the Parkinson's evidence insufficient; the Michael J. Fox Foundation and others sued over it. On 17 January 2025 the EPA said it wanted to withdraw the decision and asked for more data, and plaintiffs said they could not wait four more years. Paraquat was banned in more than 70 countries while US use stayed permitted during the review. Switzerland banned it in 1989. On 11 July 2007 the EU's Court of First Instance annulled the EU approval in a case brought by Sweden, supported by Denmark, Austria and Finland, ruling that the approval process had not adequately examined the Parkinson's link. Brazil's health surveillance agency ANVISA banned paraquat in September 2017 with a three-year transition; Brazil was the largest consumer, accounting for more than half of Syngenta's paraquat sales, and in 2016 Syngenta held 40% of a global market of about $1 billion. The agriculture ministry and the farm caucus in parliament pressed for the ban to be reversed. Unearthed, Greenpeace's investigative unit, reported that the UK exported 8,489 tonnes of banned pesticide active ingredients in 2023, 98% of it Syngenta's, including 2,771 tonnes of paraquat, all to the United States, and that the UK had made no commitment to limit the trade.

On 3 March 2026 Syngenta announced it would end Gramoxone production on 30 June and sales by 31 December 2026 at the latest, attributing the decision to competition from smaller producers. On 25 June 2026 the US Supreme Court held 7 to 2 in Monsanto v. Durnell that the federal pesticide law (FIFRA) bars state claims that would require a cancer warning not on the EPA-approved label. Part of the market that paraquat left was taken by diquat; diquat poisonings in Paraná, Brazil, rose from 1 to 3 a year to 9 in 2023. Sri Lanka banned paraquat, dimethoate and fenthion between 2008 and 2011; pesticide suicides fell 50% and all suicides 21% between 2011 and 2015, with rice yields unchanged, and because the three bans were measured together the effect of paraquat alone cannot be separated.

  1. 1958ICI sees a related compound affect the nervous system
  2. 1961ICI develops paraquat, sold as Gramoxone
  3. 1966Tremors seen in rats and mice; Chevron becomes the US distributor (1966 to 1986)
  4. 1968Autopsies show paraquat accumulating in the brain
  5. 1976Autopsy of an agricultural worker shows degeneration of substantia nigra cells
  6. 1985A Chevron note compares the legal risk to asbestos
  7. 1986Chevron stops selling paraquat, citing increased competition
  8. 1989Switzerland bans paraquat
  9. 2003Company document projects annual paraquat sales above $400 million; company mouse study finds no neuron loss
  10. 200711 July: EU Court of First Instance annuls the EU approval of paraquat
  11. 2011A 'PQ SWAT team' is working by this year at the latest; a 110-patient case-control study reports 2.5 times higher odds of reported rotenone or paraquat use among Parkinson's patients
  12. 2017September: Brazil's ANVISA bans paraquat with a three-year transition
  13. 2020October: Switzerland's Federal Council announces a ban on the export of five pesticides banned in Switzerland
  14. 2021Syngenta settles for $187.5 million without admitting liability; EPA interim decision finds the Parkinson's evidence insufficient
  15. 2022The New Lede and The Guardian publish the Paraquat Papers
  16. 2023June: further internal files on the SWAT team published
  17. 202517 January: EPA says it wants to withdraw its 2021 decision. April: settlement letter in MDL 3004, amount undisclosed; more than 5,800 federal cases
  18. 20263 March: Syngenta announces Gramoxone exit. 25 June: Monsanto v. Durnell decided 7 to 2. July: more than 8,000 federal cases, none before a jury

What was said

Claims, in the words of those who made them.

Where accounts differ

Each party's account, side by side, with its source. The record does not settle these points; it shows them.

Does paraquat cause Parkinson's disease?
Company or project
Syngenta

US and Australian regulators judge it safe; no properly designed study has established a link; more than 1,200 studies do not show causation.

The New Lede (with The Guardian)
Government and regulators
US EPA

Its 2021 interim decision found the evidence insufficient; in January 2025 it said it wanted to withdraw that decision and asked for more data.

The New Lede
Researchers
Case-control study, Iowa and North Carolina (2011)

Among 110 patients and 358 controls, patients were 2.5 times as likely to report using rotenone or paraquat; exposure was self-reported and the result covers both substances together.

Press and investigations
The New Lede

The Paraquat Papers do not show that Syngenta believed in a Parkinson's link; they show efforts to protect sales, answer outside research and influence the regulator.

The New Lede (with The Guardian)
Courts
EU Court of First Instance

Annulled the EU approval on 11 July 2007 on a challenge by Sweden, holding that the approval process had not sufficiently examined the Parkinson's link.

Public Eye
What does the settlement mean for the plaintiffs?
Company or project
Syngenta

The settlement is not an admission of causation and the cases lack merit.

The New Lede
Courts
Judge, MDL 3004 (Illinois)

Sent those who refused the settlement to a special master for meetings and depositions.

The New Lede
Communities and civil society
Plaintiffs and their lawyers

Some lawyers estimated the average payment at $100,000 or less; plaintiffs said little would remain after liens and fees.

The New Lede
Why did Chevron stop selling paraquat in 1986?
Company or project
Chevron

Cited increased competition in 1986.

The New Lede (with The Guardian)
Press and investigations
Released ICI and Chevron documents

A 1985 Chevron note compared the legal risk to asbestos.

The New Lede (with The Guardian)
Should Brazil's paraquat ban stand?
Government and regulators
ANVISA (Brazil)

Banned paraquat in September 2017 with a three-year transition.

Public Eye
Government and regulators
Brazil's agriculture ministry and parliamentary farm caucus

Pressed for the ban to be reversed.

Public Eye
Why is Syngenta ending Gramoxone production and sales?
Company or project
Syngenta

Competition from small producers.

SDSU Extension

How it looked

What was shown, beside what was recorded.

Shown

  • US and Australian regulators judge paraquat safe, and no properly designed study has established a link to Parkinson's disease.
  • More than 1,200 studies do not show causation.
  • The settlement is not an admission of causation and the cases lack merit.
    Syngenta · The New Lede
  • The decision to end Gramoxone production and sales reflects competition from smaller producers.
    Syngenta, 3 March 2026 · SDSU Extension

Recorded

  • Internal ICI and Chevron records dated 1958 to 1986 describe nervous-system effects, brain accumulation, substantia nigra degeneration in a 1976 autopsy and a 1985 note comparing the legal risk to asbestos.
  • A 2003 company mouse study found no neuron loss; a repeat by a researcher using independent scientists' method found significant neuron loss, was not published and reached the EPA around 2019.
  • Syngenta conveyed its objection to a critical scientist's EPA panel nomination through CropLife America without being named; EPA did not select the scientist in 2005 or 2010–2011.
  • A "PQ SWAT team" operated by 2011; a defence lawyer had scientists' statements edited in 2008–09; the retired head of EPA's pesticide office became a company expert at $300 an hour.
  • A 2011 study with 110 patients and 358 controls found that Parkinson's patients were 2.5 times as likely to report using rotenone or paraquat. The exposure was self-reported and the figure covers both substances.
  • Syngenta settled in 2021 for $187.5 million without admitting liability.
  • More than 8,000 federal cases were pending in July 2026; none had gone before a jury; 183 of one firm's 217 clients left the settlement.
  • EPA's 2021 interim decision found the Parkinson's evidence insufficient; on 17 January 2025 EPA said it wanted to withdraw it and ask for more data. Use remains legal in the US while the review continues.
  • In 2023 the UK exported 8,489 tonnes of banned active ingredients, 98% of them Syngenta's. All 2,771 tonnes of paraquat went to the US, and the UK gave no commitment to limit this trade.
  • On 25 June 2026 the US Supreme Court held 7 to 2 in Monsanto v. Durnell that the federal pesticide law (FIFRA) bars state-law claims that would require a warning not on the EPA-approved label.
  • In October 2020 Switzerland's Federal Council announced a ban on the export of five pesticides banned in Switzerland.
  • Part of the market left by paraquat was taken by diquat. Diquat poisonings in Paraná, Brazil, rose from 1–3 a year to 9 in 2023.
  • Sri Lanka banned paraquat, dimethoate and fenthion between 2008 and 2011. Pesticide suicides fell 50% and all suicides 21% between 2011 and 2015, with rice yields unchanged. Because the three bans were measured together, the effect of paraquat alone cannot be separated.
  • No final court ruling has settled whether paraquat causes Parkinson's disease.

Who gained

Money that reached nature, beside money that stayed elsewhere.

Reached nature or the ground

Not published
No figure published.

Gained elsewhere

Not totalled
Currency: USD · Window: 2021 to 2026. All figures cover the same period. * Estimate built from cited figures.

Responses on record

  • syngenta (2022–2023): US and Australian regulators judge paraquat safe; no properly designed study has established a Parkinson's link; later said more than 1,200 studies do not show causation. · The New Lede (with The Guardian)
  • syngenta (April 2025): The settlement is not an admission of causation and the cases lack merit. · The New Lede
  • syngenta (3 March 2026): Attributed the decision to end Gramoxone production and sales to competition from smaller producers. · SDSU Extension
  • chevron (1986): Stopped selling paraquat in 1986, citing increased competition, according to the released documents. · The New Lede (with The Guardian)
  • us-epa (2021; 17 January 2025): Found the Parkinson's evidence insufficient in its 2021 interim decision; said on 17 January 2025 that it wanted to withdraw the decision and asked for more data. · The New Lede

In court and with insurers

Every proceeding and every insurer decision on record.

Lawsuits and rulings

  1. Ongoing
    Paraquat Products Liability Litigation, MDL 3004
    US federal court, Illinois (multidistrict litigation) · Civil · Plaintiffs alleging paraquat caused Parkinson's disease → Syngenta

    A settlement letter with an undisclosed amount was signed in April 2025, when more than 5,800 federal cases were pending. By July 2026 there were more than 8,000 and none had gone before a jury. The judge sent those who refused the settlement to a special master; 183 of one firm's 217 clients left it. The New Lede

  2. 2021Settled$187.5m Millions; settlement without admission of liability
    Syngenta paraquat settlement, 2021
    United States (court not specified in the record) · Civil · Paraquat plaintiffs → Syngenta

    Syngenta settled without admitting liability.

  3. 2007-07-11Claimant won
    Sweden v. Commission, annulment of EU paraquat approval
    Court of First Instance of the European Communities · Administrative · Sweden, supported by Denmark, Austria and Finland → European Commission

    The court annulled the EU approval of paraquat, ruling that the approval process had not adequately examined the link to Parkinson's disease. Public Eye

  4. Ongoing
    Challenge to the EPA's 2021 paraquat interim decision
    US court (forum not stated) · Administrative · Michael J. Fox Foundation and others → US EPA

    The challengers contested EPA's 2021 interim decision that found the Parkinson's evidence insufficient. On 17 January 2025 EPA said it wanted to withdraw the decision and request more data; the plaintiffs said they could not wait four more years. The New Lede

Insurers

No insurer decision on record.

What nature saw

Outcomes measured on the ground, and nature's note.

Nature's report opens this page. Below: further outcomes measured on the ground.

Federal cases pending
8,000+
July 2026; none before a jury (The New Lede)
Countries that banned paraquat
70+
As reported by The New Lede, January 2025; not banned in the US, where the EPA review continues
Settlements
$187.5m (2021); 2025 amount confidential
The 2021 settlement did not admit liability
Annual sales projected in a 2003 company document
Over $400 million
Projection, not realised sales

What we don't know

Undisclosed, unproven, untried: recorded as data.

Nature

  • Not measured Harm to nature: The record holds no measurement of harm to nature.

Figures

  • Self-reported only Odds ratio: Odds of reporting rotenone or paraquat use among Parkinson's patients (110 patients, 358 controls); self-reported exposure, both substances combined.

Accounts

  • Disputed Does paraquat cause Parkinson's disease?
  • Disputed What does the settlement mean for the plaintiffs?
  • Disputed Why did Chevron stop selling paraquat in 1986?
  • Disputed Should Brazil's paraquat ban stand?
  • Disputed Why is Syngenta ending Gramoxone production and sales?

Record

  • None on record The amount of the April 2025 settlement in MDL 3004 is confidential.
  • None on record The amount Chevron paid in paraquat suits is not known.
  • None on record The 2021 settlement is given as $187.5 million in one source section and as 'at least $187.5 million' in another, which is marked as.
  • None on record No final court ruling has settled whether paraquat causes Parkinson's disease, and none of the more than 8,000 federal cases had reached a jury by July 2026.
  • Insufficient Reported but not independently verified: a federal judge threatened a plaintiffs' lawyer with sanctions in October 2025.
  • Insufficient Reported but not independently verified: Syngenta's exit closes its Huddersfield plant in England, and paraquat is less than 1% of company sales.
  • Insufficient Reported but not independently verified: California's paraquat registration was cancelled in April 2026, with stocks saleable until 2028 and other companies' products unaffected.
  • Insufficient Reported but not independently verified: UK authorities approved export of more than 28,000 tonnes of paraquat mixtures in 2018 (Public Eye).
  • Insufficient Reported but not independently verified: China banned domestic use in 2016 while continuing to export (production capacity of 105,000 tonnes a year in 2009), and about 78 million pounds reached the US from China in one year (WUFT).
  • Insufficient Reported but not independently verified: Thailand decided in 2019 to ban paraquat, delayed the ban to June 2020 and dropped glyphosate from the ban after a US official's letter.
  • Insufficient Reported but not independently verified: ChemChina bought Syngenta in 2017 for about $43 billion and merged with Sinochem in 2021.
  • None on record The sources reviewed do not list which five pesticides were covered by the Swiss export ban announced in October 2020.

Did the harm stop?

Syngenta announced in March 2026 that it would end Gramoxone production on 30 June and sales by 31 December 2026 at the latest. US use of paraquat remained permitted while the EPA review continued.

Who paid?

Syngenta paid $187.5 million in 2021 and an undisclosed amount in 2025. Plaintiffs said little would remain for them after liens and fees from payments that some lawyers estimated at $100,000 or less on average.

Sources

Voices on record: — Company or project— Government and regulators— Courts✓ Press and investigations✓ Communities and civil society✓ Researchers

Researchers

Connected cases

Related matters, and cases linked to this one through the same organisations, with the role each played in both.

Institutions

EPA
The US Environmental Protection Agency.

Carbon and conservation finance

Retired credit
A credit that has been used to make a climate claim and is permanently removed from circulation in the registry.

Science and environment

PFOA (C8) and PFAS
PFAS are a large family of human-made chemicals that persist in the environment and the body; PFOA, also called C8, is one of them and was used to make Teflon.

Law and courts

Arbitration
A private dispute process in which an appointed arbitrator, instead of a court, decides the case.